626 related articles for article (PubMed ID: 32707230)
1. Differential immune activation profile of SARS-CoV-2 and SARS-CoV infection in human lung and intestinal cells: Implications for treatment with IFN-β and IFN inducer.
Shuai H; Chu H; Hou Y; Yang D; Wang Y; Hu B; Huang X; Zhang X; Chai Y; Cai JP; Chan JF; Yuen KY
J Infect; 2020 Oct; 81(4):e1-e10. PubMed ID: 32707230
[TBL] [Abstract][Full Text] [Related]
2. Critical Role of Type III Interferon in Controlling SARS-CoV-2 Infection in Human Intestinal Epithelial Cells.
Stanifer ML; Kee C; Cortese M; Zumaran CM; Triana S; Mukenhirn M; Kraeusslich HG; Alexandrov T; Bartenschlager R; Boulant S
Cell Rep; 2020 Jul; 32(1):107863. PubMed ID: 32610043
[TBL] [Abstract][Full Text] [Related]
3. Type I and Type III Interferons Restrict SARS-CoV-2 Infection of Human Airway Epithelial Cultures.
Vanderheiden A; Ralfs P; Chirkova T; Upadhyay AA; Zimmerman MG; Bedoya S; Aoued H; Tharp GM; Pellegrini KL; Manfredi C; Sorscher E; Mainou B; Lobby JL; Kohlmeier JE; Lowen AC; Shi PY; Menachery VD; Anderson LJ; Grakoui A; Bosinger SE; Suthar MS
J Virol; 2020 Sep; 94(19):. PubMed ID: 32699094
[TBL] [Abstract][Full Text] [Related]
4. Antiviral Activity of Type I, II, and III Interferons Counterbalances ACE2 Inducibility and Restricts SARS-CoV-2.
Busnadiego I; Fernbach S; Pohl MO; Karakus U; Huber M; Trkola A; Stertz S; Hale BG
mBio; 2020 Sep; 11(5):. PubMed ID: 32913009
[TBL] [Abstract][Full Text] [Related]
5. Innate Immune Signaling and Proteolytic Pathways in the Resolution or Exacerbation of SARS-CoV-2 in Covid-19: Key Therapeutic Targets?
Sallenave JM; Guillot L
Front Immunol; 2020; 11():1229. PubMed ID: 32574272
[TBL] [Abstract][Full Text] [Related]
6. Antiviral activities of type I interferons to SARS-CoV-2 infection.
Mantlo E; Bukreyeva N; Maruyama J; Paessler S; Huang C
Antiviral Res; 2020 Jul; 179():104811. PubMed ID: 32360182
[TBL] [Abstract][Full Text] [Related]
7. Innate Immune Responses to Highly Pathogenic Coronaviruses and Other Significant Respiratory Viral Infections.
Ahmed-Hassan H; Sisson B; Shukla RK; Wijewantha Y; Funderburg NT; Li Z; Hayes D; Demberg T; Liyanage NPM
Front Immunol; 2020; 11():1979. PubMed ID: 32973803
[TBL] [Abstract][Full Text] [Related]
8. Tropism, replication competence, and innate immune responses of the coronavirus SARS-CoV-2 in human respiratory tract and conjunctiva: an analysis in ex-vivo and in-vitro cultures.
Hui KPY; Cheung MC; Perera RAPM; Ng KC; Bui CHT; Ho JCW; Ng MMT; Kuok DIT; Shih KC; Tsao SW; Poon LLM; Peiris M; Nicholls JM; Chan MCW
Lancet Respir Med; 2020 Jul; 8(7):687-695. PubMed ID: 32386571
[TBL] [Abstract][Full Text] [Related]
9. Interplay between SARS-CoV-2 and the type I interferon response.
Sa Ribero M; Jouvenet N; Dreux M; Nisole S
PLoS Pathog; 2020 Jul; 16(7):e1008737. PubMed ID: 32726355
[TBL] [Abstract][Full Text] [Related]
10. Immune environment modulation in pneumonia patients caused by coronavirus: SARS-CoV, MERS-CoV and SARS-CoV-2.
Yao Z; Zheng Z; Wu K; Junhua Z
Aging (Albany NY); 2020 May; 12(9):7639-7651. PubMed ID: 32364527
[TBL] [Abstract][Full Text] [Related]
11. Induction of interferon-gamma-inducible protein 10 by SARS-CoV infection, interferon alfacon 1 and interferon inducer in human bronchial epithelial Calu-3 cells and BALB/c mice.
Kumaki Y; Day CW; Bailey KW; Wandersee MK; Wong MH; Madsen JR; Madsen JS; Nelson NM; Hoopes JD; Woolcott JD; McLean TZ; Blatt LM; Salazar AM; Smee DF; Barnard DL
Antivir Chem Chemother; 2010 Mar; 20(4):169-77. PubMed ID: 20231782
[TBL] [Abstract][Full Text] [Related]
12. Comparative Replication and Immune Activation Profiles of SARS-CoV-2 and SARS-CoV in Human Lungs: An Ex Vivo Study With Implications for the Pathogenesis of COVID-19.
Chu H; Chan JF; Wang Y; Yuen TT; Chai Y; Hou Y; Shuai H; Yang D; Hu B; Huang X; Zhang X; Cai JP; Zhou J; Yuan S; Kok KH; To KK; Chan IH; Zhang AJ; Sit KY; Au WK; Yuen KY
Clin Infect Dis; 2020 Sep; 71(6):1400-1409. PubMed ID: 32270184
[TBL] [Abstract][Full Text] [Related]
13. Protein Coding and Long Noncoding RNA (lncRNA) Transcriptional Landscape in SARS-CoV-2 Infected Bronchial Epithelial Cells Highlight a Role for Interferon and Inflammatory Response.
Vishnubalaji R; Shaath H; Alajez NM
Genes (Basel); 2020 Jul; 11(7):. PubMed ID: 32646047
[TBL] [Abstract][Full Text] [Related]
14. An updated insight into the molecular pathogenesis, secondary complications and potential therapeutics of COVID-19 pandemic.
Jamwal S; Gautam A; Elsworth J; Kumar M; Chawla R; Kumar P
Life Sci; 2020 Sep; 257():118105. PubMed ID: 32687917
[TBL] [Abstract][Full Text] [Related]
15. Innate immune response of human alveolar type II cells infected with severe acute respiratory syndrome-coronavirus.
Qian Z; Travanty EA; Oko L; Edeen K; Berglund A; Wang J; Ito Y; Holmes KV; Mason RJ
Am J Respir Cell Mol Biol; 2013 Jun; 48(6):742-8. PubMed ID: 23418343
[TBL] [Abstract][Full Text] [Related]
16. SARS-CoV-2 Isolates Show Impaired Replication in Human Immune Cells but Differential Ability to Replicate and Induce Innate Immunity in Lung Epithelial Cells.
Jiang M; Kolehmainen P; Kakkola L; Maljanen S; Melén K; Smura T; Julkunen I; Österlund P
Microbiol Spectr; 2021 Sep; 9(1):e0077421. PubMed ID: 34378952
[TBL] [Abstract][Full Text] [Related]
17. Contribution of monocytes and macrophages to the local tissue inflammation and cytokine storm in COVID-19: Lessons from SARS and MERS, and potential therapeutic interventions.
Jafarzadeh A; Chauhan P; Saha B; Jafarzadeh S; Nemati M
Life Sci; 2020 Sep; 257():118102. PubMed ID: 32687918
[TBL] [Abstract][Full Text] [Related]
18. Immune Responses to SARS-CoV, MERS-CoV and SARS-CoV-2.
İnandıklıoğlu N; Akkoc T
Adv Exp Med Biol; 2020; 1288():5-12. PubMed ID: 32514817
[TBL] [Abstract][Full Text] [Related]
19. Type I Interferon Susceptibility Distinguishes SARS-CoV-2 from SARS-CoV.
Lokugamage KG; Hage A; de Vries M; Valero-Jimenez AM; Schindewolf C; Dittmann M; Rajsbaum R; Menachery VD
J Virol; 2020 Nov; 94(23):. PubMed ID: 32938761
[TBL] [Abstract][Full Text] [Related]
20. Human Nasal and Lung Tissues Infected
Alfi O; Yakirevitch A; Wald O; Wandel O; Izhar U; Oiknine-Djian E; Nevo Y; Elgavish S; Dagan E; Madgar O; Feinmesser G; Pikarsky E; Bronstein M; Vorontsov O; Jonas W; Ives J; Walter J; Zakay-Rones Z; Oberbaum M; Panet A; Wolf DG
J Virol; 2021 Jun; 95(14):e0013021. PubMed ID: 33893170
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
